Last reviewed · How we verify

levo-bupicaine

Basque Health Service · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

levo-bupicaine is a Small molecule drug developed by Basque Health Service. It is currently FDA-approved.

Levo-bupicaine is a small molecule local anesthetic. It has been studied in clinical trials for its use as a local anesthetic, particularly in the context of surgical procedures such as modified radical mastectomy with expander.

At a glance

Generic namelevo-bupicaine
SponsorBasque Health Service
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about levo-bupicaine

What is levo-bupicaine?

levo-bupicaine is a Small molecule drug developed by Basque Health Service.

Who makes levo-bupicaine?

levo-bupicaine is developed and marketed by Basque Health Service (see full Basque Health Service pipeline at /company/basque-health-service).

What development phase is levo-bupicaine in?

levo-bupicaine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing